Sweden
Nyctea Technologies is a biotechnology startup founded in 2020 and headquartered in Sweden. The company specializes in the creation of new purification and administration methods for biopharmaceuticals using electronically activated biomolecule control.
With its patent-pending technology, Nyctea Technologies offers electronically activated purification of biomolecules for biopharmaceutical and protein production. The company's innovative approach involves building functionalized polymer surfaces that can capture and release biomolecules with high specificity and capacity at the press of a button.
The latest funding round saw Nyctea Technologies secure a kr1.50MConvertible Note investment on 27 September 2022, with Chalmers Ventures participating as the lead investor.
Overall, Nyctea Technologies' disruptive technology has the potential to streamline and digitalize the complex process of biopharmaceutical and protein manufacturing, offering a promising prospect for investors in the biotechnology sector.
